iBio, Inc. Common Stock (IBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.28 (+2.40%), Market cap $0.09B, 52-week low–high $0.57 ~ $3.07.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells
Financial statements, price targets, institutional (13F) holdings and related news for iBio, Inc. Common Stock are updated in real time on BlackAll Trade.
iBio, Inc. Common Stock trades at $1.28 (+2.40%). Real-time quotes and charts are available on BlackAll Trade.
iBio, Inc. Common Stock has a market cap of about $0.09B.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology p